Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: A randomized, placebo-controlled trial

Depression and Anxiety

Volumn 27, Issue 10, 2010, Pages 964-976

  Liebowitz, Michael ^a   Lam, Raymond W ^b   Lepola, Ulla ^c   Datto, Catherine ^d   Sweitzer, Dennis ^d   Eriksson, Hans ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Psychiatric Research Clinic of Kuopio   (Finland)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Atypical antipsychotics; Depression; Efficacy; Major depressive disorder; Monotherapy; Phase III study; Quetiapine; Tolerability

Indexed keywords

PLACEBO; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SEVERITY OF ILLNESS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; HYPOTHYROIDISM; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; THYROTROPIN BLOOD LEVEL; WEIGHT GAIN; XEROSTOMIA; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649499136     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20740     Document Type: Article

References (42)

1. Shelton CI. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? J Clin Psychiatry 2004;65:29-33.
2. Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 1998;7:443-449. (Pubitemid 128435151)
3. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415-426. (Pubitemid 41341413)
4. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007;8:67-104. (Pubitemid 46690921)
5. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry 2007;68:17-25. (Pubitemid 47184567)
6. Trivedi MH, Hollander E, Nutt D, et al. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008;69:246-258. (Pubitemid 351469268)
7. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 2007;68:26-34. (Pubitemid 47184568)
8. Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351-1360. (Pubitemid 40905587)
9. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609. (Pubitemid 44772737)
10. Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post-hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008;69:769-782. (Pubitemid 351838686)
11. Young AH, McElroy S, Chang W, et al. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I). Bipolar Disord 2008;10:1 (Abstract).
12. McElroy S, Young AH, Carlsson A, et al. Double-blind, randomized, placebo-controlled study of quetiapine and parox-etine in adults with bipolar depression (EMBOLDEN II). Bipolar Disord 2008;10:1 (Abstract).
13. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-539.
14. Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) mono-therapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2010; Aug 4 Epub ahead of print.
15. Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo controlled study. CNS Spectr 2009;14:299-313.
16. Bauer M, Pretorius HW, Constant EL, et al. Extended release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-549.
17. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment-a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010;13:917-932.
18. (1A) agonist, as a putative mediator of quetiapine's antidepres-sant activity. Neuropsychopharmacology 2008;33:2303-2312.
19. Goldstein JM, Nyberg S, Brecher M. Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. Eur Psychiatry 2008;23:S202 (Abstract).
20. Nyberg S, Takano A, Jucaite A, et al. PET-measured occupancy of the NET by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects. Eur Neuropsychopharmacol 2008;18:S270 (Abstract).
21. Goldstein JM, Christoph G, Grimm S, et al. Quetiapine's antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuro-psychopharmacol 2007;17:S401 (Abstract).
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389. (Pubitemid 9136500)
24. National Institute of Mental Health. CGI clinical global impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU Assessment Battery. 2. Rev ed. Chevy Chase, MD: US
25. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:217-222.
26. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
27. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharma-col Bull 1993;29:321-326. (Pubitemid 23311543)
28. Buysse DJ, Reynolds III CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213. (Pubitemid 19144991)
29. The Anxiety Disease. New York: Scribner; 1996.
30. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000;176:363-368.
31. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87. (Pubitemid 28305526)
32. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
33. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676. (Pubitemid 19154942)
34. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, editor. ECDEU Assessment Manual for Psychopharma-cology-Revised (DHEW Publ no ADM 766-338). Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:534-537.
35. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222.
36. Robert P, Montgomery SA. Citalopram in doses of 20-60mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10:29-35.
37. Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003; 64:1349-1356. (Pubitemid 37490241)
38. Kocsis JH, Thase ME, Trivedi MH, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry 2007;68:1014-1023. (Pubitemid 47340320)
39. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449-454. (Pubitemid 26362308)
40. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002;63:1156-1163. (Pubitemid 36084061)
41. Weiden PJ. EPS profiles: the atypical antipsychotics: are not all the same. J Psychiatr Pract 2007;13:13-24. (Pubitemid 46148428)
42. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193:279-288.